Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry

Research output: Contribution to journalArticle

Standard

Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. / Farge, D; Passweg, J; van Laar, JM; Marjanovic, Z; Besenthal, C; Finke, J; Peter, HH; Breedveld, FC; Bacon, Paul.

In: Annals of the Rheumatic Diseases, Vol. 63, No. 8, 01.01.2004, p. 974-81.

Research output: Contribution to journalArticle

Harvard

Farge, D, Passweg, J, van Laar, JM, Marjanovic, Z, Besenthal, C, Finke, J, Peter, HH, Breedveld, FC & Bacon, P 2004, 'Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry', Annals of the Rheumatic Diseases, vol. 63, no. 8, pp. 974-81. https://doi.org/10.1136/ard.2003.011205

APA

Farge, D., Passweg, J., van Laar, JM., Marjanovic, Z., Besenthal, C., Finke, J., Peter, HH., Breedveld, FC., & Bacon, P. (2004). Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Annals of the Rheumatic Diseases, 63(8), 974-81. https://doi.org/10.1136/ard.2003.011205

Vancouver

Author

Farge, D ; Passweg, J ; van Laar, JM ; Marjanovic, Z ; Besenthal, C ; Finke, J ; Peter, HH ; Breedveld, FC ; Bacon, Paul. / Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. In: Annals of the Rheumatic Diseases. 2004 ; Vol. 63, No. 8. pp. 974-81.

Bibtex

@article{35596906d62741a7b464e37b9aed0b70,
title = "Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry",
abstract = "OBJECTIVE: To analyse the durability of the responses after haematopoietic stem cell transplantation (HSCT) for severe systemic sclerosis (SSc) and determine whether the high transplant related mortality (TRM) improved with experience. This EBMT/EULAR report describes the longer outcome of patients originally described in addition to newly recruited cases. METHODS: Only patients with SSc, treated by HSCT in European phase I-II studies from 1996 up to 2002, with more than 6 months of follow up were included. Transplant regimens were according to the international consensus statements. Repeated evaluations analysed complete, partial, or non-response and the probability of disease progression and survival after HSCT (Kaplan-Meier). RESULTS: Given as median (range). Among 57 patients aged 40 (9.1-68.7) years the skin scores improved at 6 (n = 37 patients), 12 (n = 30), 24 (n = 19), and 36 (n = 10) months after HSCT (p",
author = "D Farge and J Passweg and {van Laar}, JM and Z Marjanovic and C Besenthal and J Finke and HH Peter and FC Breedveld and Paul Bacon",
year = "2004",
month = jan,
day = "1",
doi = "10.1136/ard.2003.011205",
language = "English",
volume = "63",
pages = "974--81",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "8",

}

RIS

TY - JOUR

T1 - Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry

AU - Farge, D

AU - Passweg, J

AU - van Laar, JM

AU - Marjanovic, Z

AU - Besenthal, C

AU - Finke, J

AU - Peter, HH

AU - Breedveld, FC

AU - Bacon, Paul

PY - 2004/1/1

Y1 - 2004/1/1

N2 - OBJECTIVE: To analyse the durability of the responses after haematopoietic stem cell transplantation (HSCT) for severe systemic sclerosis (SSc) and determine whether the high transplant related mortality (TRM) improved with experience. This EBMT/EULAR report describes the longer outcome of patients originally described in addition to newly recruited cases. METHODS: Only patients with SSc, treated by HSCT in European phase I-II studies from 1996 up to 2002, with more than 6 months of follow up were included. Transplant regimens were according to the international consensus statements. Repeated evaluations analysed complete, partial, or non-response and the probability of disease progression and survival after HSCT (Kaplan-Meier). RESULTS: Given as median (range). Among 57 patients aged 40 (9.1-68.7) years the skin scores improved at 6 (n = 37 patients), 12 (n = 30), 24 (n = 19), and 36 (n = 10) months after HSCT (p

AB - OBJECTIVE: To analyse the durability of the responses after haematopoietic stem cell transplantation (HSCT) for severe systemic sclerosis (SSc) and determine whether the high transplant related mortality (TRM) improved with experience. This EBMT/EULAR report describes the longer outcome of patients originally described in addition to newly recruited cases. METHODS: Only patients with SSc, treated by HSCT in European phase I-II studies from 1996 up to 2002, with more than 6 months of follow up were included. Transplant regimens were according to the international consensus statements. Repeated evaluations analysed complete, partial, or non-response and the probability of disease progression and survival after HSCT (Kaplan-Meier). RESULTS: Given as median (range). Among 57 patients aged 40 (9.1-68.7) years the skin scores improved at 6 (n = 37 patients), 12 (n = 30), 24 (n = 19), and 36 (n = 10) months after HSCT (p

UR - http://www.scopus.com/inward/record.url?scp=3242658935&partnerID=8YFLogxK

U2 - 10.1136/ard.2003.011205

DO - 10.1136/ard.2003.011205

M3 - Article

C2 - 15249325

VL - 63

SP - 974

EP - 981

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 8

ER -